Inhibrx Biosciences, Inc.
NASDAQInhibrx Biosciences has put in one of biotech's more dramatic single-month moves — up 45% to $121.17 — yet short sellers haven't flinched, and two company insiders remain on the SEC's activist register with Schedule 13D filings still outstanding. The short position is the defining tension here. At 22.1% of the free float, roughly 3.2 million shares are still sold short — and that…
INBX short interest surges 34% in one week to 18.8% of float, driven by positioning ahead of earnings on May 15.
Snapshot as of 24 Sept 2026
Inhibrx Biosciences has put in one of biotech's more dramatic single-month moves — up 45% to $121.17 — yet short sellers haven't flinched, and two company insiders remain on the SEC's activist register with Schedule…
Inhibrx Biosciences enters its August 14 earnings event carrying one of the heavier short burdens in the biotech space — short interest at nearly 23% of the free float — yet the borrow market tells a surprisingly…
Inhibrx Biosciences heads into its May 15 earnings call sitting on a 70% one-month rally driven by clinical data — yet short sellers remain deeply embedded, setting up one of the more charged setups in small-cap…
INBX has done something remarkable in the past month: it has more than doubled, rising 115% to $134.35 while carrying more than a quarter of its free float in short positions. That combination — a heavily shorted…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for INBX — free to start on ORTEX.
Sign up for free →Open INBX on ORTEX